UltraGreen.ai Set to Benefit From Greater Indocyanine Green Demand — Market Talk

About this update from Ultragreen.ai Limited

UltraGreen.ai stands to benefit from greater indocyanine green demand across both established and emerging surgical procedures, Phillip Securities' Hashim Osman says in commentary. ICG usage is expected to increase by double digits across the majority of procedures using fluorescence-guided surgery by 2028, the analyst says. The main driver is ICG becoming a standard of care, with major surgical societies incorporating ICG into their clinical guidelines, the analyst adds. The Singapore-based company supplies imaging agents such as indocyanine green for fluorescence-guided surgery. The brokerage initiates coverage of the stock with a buy rating and a target price of US$1.92. Shares are 0.8% higher at US$1.24. ([email protected])

View stock analysis, news, and events for Ultragreen.ai Limited